- Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
- Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
- Natera Reports First Quarter 2024 Financial Results
- New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
- Natera to Report its First Quarter 2024 Results on May 9
- Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
- Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
- Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
- Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
- Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
More ▼
Key statistics
As of last trade Natera Inc (NTRA:NSQ) traded at 109.00, -0.99% below its 52-week high of 110.09, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 108.40 |
---|---|
High | 110.09 |
Low | 107.41 |
Bid | 109.03 |
Offer | 109.13 |
Previous close | 107.51 |
Average volume | 1.05m |
---|---|
Shares outstanding | 122.80m |
Free float | 117.64m |
P/E (TTM) | -- |
Market cap | 13.20bn USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of May 24 2024 18:12 BST.
More ▼